Ranolazine Tablet, Film Coated, Extended Release
Product Images NDC 73141-022
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 73141-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A2a Integrated Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Container-1000mg-60tablets (Container 1000mg 60tablets)
This is a description of Ranolazine Extended-Release Tablets, with each tablet containing 1,000 mg of ranolazine. The instruction advises swallowing the tablet whole, not crushing, breaking, or chewing it. It is a prescription medication, and the package includes 60 tablets. The usual dosage information can be found in the package insert. The tablets should be stored at 25°C (77°F) with excursions allowed between 15-30°C (59-86°F). The package is child-resistant and should be kept out of children's reach. The tablets are film-coated and manufactured by A2A Integrated Pharmaceuticals.*
Container-500mg-60tablets (Container 500mg 60tablets)
This is a description of Ranolazine Extended-Release Tablets with a dosage of 500 mg per tablet. It contains important instructions such as swallowing the tablet whole and not crushing, breaking, or chewing it. The usual dosage information can be found in the package insert. Storage instructions recommend keeping the tablets at 25°C; excursions between 15° to 30°C are acceptable. The packaging is child-resistant and should be kept out of reach of children. The tablets are distributed by A2A Integrated Pharmaceuticals.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.